Managed access program for ribociclib
Treatments studied
Part of Cancer, Skin clinical trials.
This program provides ribociclib (a targeted cancer therapy) to patients with serious or life-threatening diseases who have no other satisfactory treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard treatments have been exhausted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor must request the medication for you.
- You have a serious or life-threatening condition.
- You have no comparable or satisfactory alternative treatment available.
- You cannot participate in a clinical trial.
- Your doctor and the program specialists agree that the potential benefit justifies the risks.
- The request is allowed under your country's laws and regulations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This program provides access to an experimental medicine called alpelisib (also known as BYL719) for people with serious conditions who have no other treatment options and cannot participate in clinical trials. If a licensed doctor requests it, and you meet the criteria, you may be able to receive this medicine through a managed access program.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial checks how well people stick to their prescribed ribociclib (Kisqali) plus aromatase inhibitor treatment for early-stage, hormone-receptor-positive, HER2-negative breast cancer, and monitors for side effects. It focuses on making sure patients are safe and supported while taking their medication.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.